LRRK2 and Parkinson disease: Godena et al. found that PD-associated LRRK2 mutations inhibit axonal transport and cause locomotor deficits; these changes were found to be significantly reversed by HDAC6 inhibitors such as trichostatin A, tubastatin A (TBA) and a SIRT2 inhibitor, AGK2 [209].